Are those quoted success figures for drugs that are already approved translating into new indications or new unapproved drugs? I know the answer just thought you might want to correct your post so you can't be accused of trying to mislead. So, there is risk and time involved in bring a drug to market for a new indication. Who knew? Amazing insight. The issue Clinuvel shareholders have is the chance of success is not priced in and it is frustrating compared to our peers.
Ann: Media release - First stroke patient with afamelanotide, page-16
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
0.220(1.51%) |
Mkt cap ! $741.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $1.156M | 78.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 478 | $15.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.32 | 51 | 1 |
View Market Depth
| Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |